Kevin C. Zorn, MD, FRCSC, FACS

Kevin C. Zorn, MD, FRCSC, FACS

Kevin C. Zorn, MD, FACS, FRCSC, is the founder of the BPH Canada Prostate Institute, a personalized, private, prostate solution center founded in 2023 to offer all approved BPH therapies to Canadian men, and director of Robotic & MIS BPH Prostate Surgery, Mont-Royal Surgical Center. Dr. Zorn is a former associate professor of urology at the University of Montreal (CHUM) and the University of Chicago, sub-specializing in robotic surgery and benign prostatic hyperplasia (BPH) surgical care. 

Dr. Zorn attended McGill University for his pre-med program, his medical degree, and his residency in urological surgery. He became a fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a two-year fellowship in oncology and endourology at the University of Chicago. In 2007, he became American Board of Urology certified in urology and a fellow of the American College of Surgeons.

Research and innovation have been the hallmarks of Dr. Zorn’s career. Among his many firsts, he was the first in Canada and Québec to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies including the Clarius and ButterflyIQ point-of care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. He is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques. 

Dr. Zorn is the senior author of the Male lower urinary tract symptoms (LUTS)/BPH guidelines for the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. With such accolades, Dr. Zorn has become a sought-after speaker, teacher and researcher. He has traveled to lecture, teach, and proctor surgery around the world, and is intimately involved with the development of several pioneering BPH technologies.  In 2024, Dr. Zorn retired from his position at the University of Montreal to dedicate his full clinical practice to BPH Canada.

Disclosures:

Talks by Kevin C. Zorn, MD, FRCSC, FACS

Rezum, Stents

Rezum, Stents

Posted by | Sep 2024

Kevin C. Zorn, MD, FACS, FRCSC, addresses the challenges and advancements in managing benign prostatic hyperplasia (BPH), focusing on minimally invasive surgical techniques. In this 17-minute presentation, he highlights the limitations of traditional treatments, such as transurethral resection of the prostate (TURP), and a growing demand for effective and less invasive alternative options.

Dr. Zorn explores the evolution of BPH treatments, discussing the importance of finding office-based, quick, and cost-effective solutions. He describes various less invasive technologies, including UroLift, Rezūm, and novel stent devices like iTind and Optilume.

Zorn underscores the variability in patient outcomes based on prostate anatomy and tissue composition, noting the importance of personalized treatment approaches. Moving towards a more tailored approach, similar to the precision seen in prostate cancer management, considers prostate size and tissue composition.

Read More
Overview of Current MIST: Practical Considerations

Overview of Current MIST: Practical Considerations

Posted by | Aug 2024

Kevin C. Zorn, MD, FRCSC, FACS, provides an authoritative overview of current minimally invasive surgical techniques (MIST) for the treatment of benign prostatic hyperplasia (BPH). His analysis emphasizes the advancements in MIST and their role in providing effective and patient-friendly alternatives to traditional surgical approaches.

Dr. Zorn highlights the primary MIST options currently available, including transurethral resection of the prostate (TURP), photoselective vaporization of the prostate (PVP), holmium laser enucleation of the prostate (HoLEP), and newer techniques such as water vapor thermal therapy and prostatic urethral lift (PUL). The procedural nuances of each MIST option are discussed in detail.

Dr. Zorn examines the outcomes and benefits of MIST as well as the challenges and limitations of the procedures. Future directions in MIST are considered, with Dr. Zorn highlighting ongoing research and innovation to further refine these techniques and expand their applicability. The integration of advanced imaging technologies and the development of novel therapeutic devices hold promise for enhancing the precision and effectiveness of MIST.

Read More
Water Vapor Thermal Therapy. How I Do It

Water Vapor Thermal Therapy. How I Do It

Posted by | Aug 2024

Kevin C. Zorn, MD, FRCSC, FACS, analyzes water vapor thermal therapy for the treatment of benign prostatic hyperplasia (BPH), focusing on its application, benefits, and procedural techniques. His discussion highlights the efficacy and minimally invasive nature of this therapy, making it an appealing option for patients seeking relief from BPH symptoms.

Dr. Zorn explains the mechanism of water vapor thermal therapy, which involves the delivery of steam directly into the prostate tissue. He outlines the procedural steps, starting with patient preparation and anesthesia. Dr. Zorn details the insertion of the transurethral device and the precise delivery of water vapor to the targeted prostate zones.

The advantages of water vapor thermal therapy are discussed extensively. Dr. Zorn highlights its high safety profile, low risk of complications, and significant improvement in urinary symptoms and quality of life. He also notes the durability of the treatment outcomes. Challenges and potential complications are addressed, including transient dysuria, hematuria, and urinary retention.

Future directions for water vapor thermal therapy include ongoing research to refine techniques, improve patient outcomes, and expand the indications for this treatment. Dr. Zorn highlights the potential for combining this therapy with other minimally invasive treatments to enhance efficacy and broaden its applicability.

Read More

Join the GRU Community

- Why Join? -